Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!

FIIs reduce stake in over 250 firms in past year; what should investors do?

Out of 254 companies, 93 have fallen more than 50 percent in the last one year

June 30, 2020 / 09:52 AM IST

Foreign investors who were net sellers in 8 out of the last 12 months have reduced stake in over 250 companies in the 4 quarters of the past year. Although on an overall basis, FIIs were net buyers with little over Rs 5,000 crore, data from AceEquity showed.

Foreign investors' selling decisions could be based on valuations, corporate governance issues, fall in demand, or just profit-taking. Many of the stocks in which FIIs have pulled down their stake are from financials, pharma, capital goods, tourism, and infrastructure companies.

There are as many as 254 companies in which FIIs have reduced their stake, including Sun Pharma, Dabur India, Cipla, HCL Technologies and Jubilant FoodWorks.

Out of 254 companies, 93 have fallen more than 50 percent in the last one year. These include PC Jeweller, Future Retail, Sadbhav Engineering, Cox & Kings, Manpasand Beverages, Magma Fincorp, and Dewan Housing Finance.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

“FIIs reduce stakes for many reasons like stretched valuations, bad corporate governance, increasing competition etc. As you pointed out FIIs have reduced stake in many bluechip companies like Jubilant FoodWorks, Nestle India, Alembic Pharma, Cipla, Dabur,” Atish Matlawala, Sr Analyst, SSJ Finance & Securities told Moneycontrol.

“We believe FIIs have sold these companies purely on the basis of valuations and would buy again when valuations become attractive. There are also few companies in the list where the standard of corporate governance is way below par so that could be the reason why FIIs exited the stocks,” he said.


Note: Here is the list of those 93 stocks. They have fallen more than 50% in the last 1 year

FIIs decreasing 1



FII decreasing 2


FII Decreasing 3

What should investors do?

There are many small & midcap companies in which FIIs have reduced their stake consistently in the last four quarters. One possible reason as pointed out by analysts is a slowdown in demand and a fall in economic activity.

Small & midcap stocks have been in a bear market since 2018 while benchmark indices entered the bear market only in 2020. However, investors should take note of the list as a reference point to shortlist stocks.

“Apart from FIIs interest, analysing company’s past financial track record, promoter background, balance sheet, cash flows, valuations, and growth prospects are extremely important,” Ajit Mishra, VP Research, Religare Broking told Moneycontrol.

Booking profits or exiting completely from the stocks should be based on doing a proper study of the recent management commentary related to the previous quarter results and future prospects of the business especially during COVID times.

Apart from that, any policy changes in the sector due to COVID could impact the sector and the companies in a negative way. Stock with any kind of corporate governance issues should be altogether avoided, suggest experts.

Which are top buys?

So can we say all stocks in which FIIs have reduced stake are sell? Analysts are of the view that there are select stocks which investors can look at for the long term.

“Keeping purview of COVID-19 and its effects, in my opinion, Polycab India Ltd., Avanti Feeds Ltd., HDFC Life Insurance Co Ltd., and Vinati Organics Ltd. might do well in coming time if investors keep these stocks for a long term,” Gaurav Garg, Head of Research CapitalVia Global Research Limited- Investment Advisor told Moneycontrol.

“Manpasand Beverages Ltd., Jet Airways (India) Ltd., Eveready Industries (India) Ltd., are the stocks which investors should avoid due to challenged corporate governance norms and their own fundamental problems,” he said.

Matlawala of SSJ Finance & Securities said that he would advise investors to stay away from companies like Reliance Capital, Cox & Kings, Manpasand beverages, Dewan Housing, Sintex Plastics, etc which are on the verge of collapse or have already collapsed.

“Companies like Dabur India, Page Industries, Tata Metaliks, 3M India, United breweries, Gillette India, VIP Industries is on our buy list,” he said.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Kshitij Anand is the Editor Markets at Moneycontrol.

stay updated

Get Daily News on your Browser
Sections